文献速递核素与放射性配体治疗放射性药物与辐射防护肿瘤 PET/CT

TheraPb 1b期:212Pb-ADVC001在PSMA阳性转移性去势抵抗性前列腺癌中的首次人体剂量递增与优化研究

TheraPb Phase 1b: First-in-Human Dose-Escalation and Optimization Study of 212Pb-ADVC001 in PSMA-Positive Metastatic Androgen Pathway Modulation-Resistant Prostate Cancer.
PubMed 文献 · J Nucl Med · 2026-10-23

TheraPb(NCT05720130)是一项首次人体剂量递增与优化研究,评估PSMA靶向α核素治疗药物212Pb-ADVC001在转移性雄激素通路调节抵抗性前列腺癌(mAPM-R)患者中的安全性、耐受性和疗效。22例经多线治疗的患者接受60–200 MBq、间隔1–6周、最多6次的剂量递增方案,未观察到剂量限制性毒性(DLT),未达到最大耐受剂量,最常见治疗相关不良事件为1–2级口干(82%)和恶心(64%)。推荐的2期剂量(RP2D)为160和200 MBq,在该剂量水平下80%(12/15)患者PSA下降≥50%,中位影像学无进展生存期(rPFS)为11.2个月(95%CI 2.0–不可估计),RECIST可评估的5例患者客观缓解率(ORR)为100%。

要点

  • 212Pb-ADVC001在60–200 MBq(含每周给药)范围内耐受良好,无DLT、未达最大耐受剂量、无4–5级或严重治疗相关不良事件。
  • RP2D为160和200 MBq,该剂量下80%患者PSA下降≥50%,中位rPFS为11.2个月(95%CI 2.0–不可估计)。
  • RP2D下RECIST可评估的5例患者中心确认客观缓解率为100%,两个RP2D正在2期研究中评估。

核心结论

  • 212Pb-ADVC001在既往多线治疗的mAPM-R患者中耐受良好(最高至200 MBq,含每周给药),并显示出鼓舞人心的抗肿瘤活性。
  • 160和200 MBq两个RP2D正在2期研究中继续评估。

研究设计与样本

  • TheraPb(NCT05720130)为首次人体剂量递增与优化研究,采用interval 3+3设计,共7个剂量- schedule队列。
  • 入组22例进展性mAPM-R患者,既往接受≥1种雄激素受体通路抑制剂和≥1种紫杉类化疗(除非禁忌/拒绝)。
  • 212Pb-ADVC001剂量60–200 MBq,按预设间隔每6、4、2或1周给药,最多6次。
  • 主要终点为DLT和不良事件以确定RP2D;次要终点包括PSA反应、ORR和rPFS。

主要发现

  • 中位随访14.1个月(IQR 8.8–17.1),未观察到DLT,未达到最大耐受剂量。
  • 最常见治疗相关不良事件为口干(18/22例[82%],均为1–2级)和恶心(14/22例[64%],均为1–2级);无4–5级或严重治疗相关不良事件。
  • RP2D(160和200 MBq)下,12/15例(80%)患者PSA下降≥50%,自C1D1起中位rPFS为11.2个月(95%CI 2.0–不可估计)。
  • ORR为100%,RP2D治疗的5例RECIST可评估患者均获中心确认的客观缓解。

关键数值与推荐

  • RP2D选定为160和200 MBq。
  • RP2D下PSA下降≥50%比例为12/15(80%)。
  • RP2D下自C1D1起中位rPFS为11.2个月(95%CI 2.0–不可估计)。
  • RP2D下RECIST可评估患者ORR为100%(5/5)。

临床怎么用

  • 对于既往接受过雄激素受体通路抑制剂和紫杉类化疗的PSMA阳性mAPM-R患者,212Pb-ADVC001 160或200 MBq方案显示出可接受的早期安全性和初步抗肿瘤活性。
  • 治疗相关不良事件以1–2级口干和恶心为主,未出现4–5级或严重治疗相关不良事件,支持进一步在2期研究中评估。

局限性

  • 样本量较小(22例),随访时间有限(中位14.1个月),rPFS的95%CI上限不可估计。
  • ORR基于仅5例RECIST可评估患者,需更大样本验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

[212Pb]Pb-ADVC001 (212Pb-ADVC001) is a prostate-specific membrane antigen (PSMA)-targeted radiopharmaceutical therapy with high linear energy transfer derived predominantly from the alpha-emission of its 212Pb payload which, upon decay, delivers potent ionizing radiation directly to the tumor. TheraPb (NCT05720130) is a first-in-human dose-escalation and optimization study evaluating 212Pb-ADVC001 in metastatic androgen pathway modulation-resistant prostate cancer (mAPM-R, formerly metastatic castration-resistant prostate cancer). Phase 1 results, including available long-term safety and efficacy outcomes, are presented. Methods: Participants with progressive mAPM-R previously treated with ≥1 androgen-receptor pathway inhibitor and ≥1 taxane chemotherapy (unless contraindicated/declined) were enrolled. Escalating doses of 60-200 MBq 212Pb-ADVC001 were administered at prespecified intervals every 6, 4, 2, or 1 week(s) for up to 6 doses across 7 dose-schedule cohorts (interval 3 + 3 design). The primary objective was to determine the recommended phase 2 dose (RP2D) with primary endpoints of dose-limiting toxicities (DLTs) and adverse events (AEs). Secondary endpoints included prostate-specific antigen (PSA) response, overall response rate (ORR), and radiographic progression-free survival (rPFS). Results: Twenty-two participants were enrolled, with a median follow-up of 14.1 months (IQR 8.8-17.1). No DLTs were observed and the maximum tolerated dose was not reached. The most common treatment-related AEs (TRAE) were dry mouth (18/22 participants [82%], all grade 1-2) and nausea (14/22 participants [64%], all grade 1-2); there were no grade 4-5 or serious TRAEs. The selected RP2D are 160 and 200 MBq. At these dose levels, 12/15 (80%) participants had a PSA decline of ≥50% and the median rPFS from C1D1 was 11.2 months (95% CI 2.0-not estimable) as of data cutoff. ORR was 100%, with centrally confirmed objective responses in all 5 Response Evaluation Criteria in Solid Tumours (RECIST)-evaluable participants treated at the RP2D. Conclusion: 212Pb-ADVC001 was well tolerated up to 200 MBq, including at weekly dosing, and showed encouraging anti-tumor activity in pretreated mAPM-R. Two RP2D, 160 and 200 MBq, are under evaluation in phase 2.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Hansen AR, Pattison DA, Goh JC, et al. TheraPb Phase 1b: First-in-Human Dose-Escalation and Optimization Study of 212Pb-ADVC001 in PSMA-Positive Metastatic Androgen Pathway Modulation-Resistant Prostate Cancer. J Nucl Med. 2026. PMID: 42919672. doi:10.2967/jnumed.126.274089

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。